The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...
Citadel, the hedge fund owned by billionaire Ken Griffin, has taken a short position in GlaxoSmithKline (NYSE:GSK), a British ...
The world’s most profitable hedge fund has started betting against shares in GSK (GSK), the first significant short on the FTSE 100 drugmaker’s ...
GlaxoSmithKline Pharmaceuticals on Friday said its net profit increased over five-fold to Rs 229 crore for the third quarter ended December 31, 2024.
GlaxoSmithKline Pharmaceuticals reports a five-fold jump in net profit for the third quarter ending December 31, 2024, ...
GlaxoSmithKline Pharmaceuticals reported a significant increase in net profit to Rs 229 crore for the third quarter ending ...
Houston-based Nabors Energy Transition Corp. II (Nasdaq: NETD), a special purpose acquisition company, will merge with Florida-based e2Companies LLC, which provides solutions for on-site power ...
Hosted on MSN1d
GSK Pharma Q3 results 2025: PAT ZOOMS 402% YoY, Revenue at Rs 949 cr - Check quarterly earningsGlaxoSmithKline Pharma Ltd announced its Q3 results today posting a solid jump in its net profit. Consolidated PAT for the ...
Glaxosmithkline Pharmaceuticals reported a profit of Rs 230 crore in third quarter, a 400% year-on-year jump from Rs 46 crore ...
In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback